A Food and Drug Administration inspection that took place at Moderna’s (MRNA) facility in Norwood, Massachusetts on Sept. 11-21 found quality control lapses, including with equipment used to manufacture drug substance for its COVID-19 vaccine, according to a report obtained by Reuters via a Freedom of Information Act request. The plant that was inspected is used to manufacture the company’s COVID shot Spikevax and an experimental mRNA cancer vaccine being developed with Merck (MRK), noted Reuters’ Patrick Wingrove.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRNA:
- Leerink skeptical on sustainability of Moderna rally given eroding fundamentals
- Moderna call volume above normal and directionally bullish
- Early notable gainers among liquid option names on December 14th
- Unusually active option classes on open December 14th
- Moderna’s (NASDAQ:MRNA) Positive Melanoma Trial Data Sparks Stock Surge